AGRX Agile Therapeutics Inc.

+0.04  (1%)
Previous Close 3.65
Open 3.62
Price To book 3.03
Market Cap 126147602
Shares 34,186,342
Volume 120,017
Short Ratio 1.72
Av. Daily Volume 622,846

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Further CRL issued December 22, 2017.
Contraceptive patch

Latest News

  1. New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated — Consolidated Revenues, Company Growth, and Expectations for 2018
  2. Analyst Remains Confident In Corium Despite Partner's Bad FDA News
  3. Agile stock craters after FDA declines to approve contraceptive patch for second time
  4. Agile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA
  5. FDA declines to approve Agile's contraceptive patch
  6. Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
  7. Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?
  8. With FDA Approvals in Sight, Will Synergy Pharmaceuticals and Agile Therapeutics Skyrocket as H.C Wainwright Predicts?
  9. Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?
  10. Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts
  11. What Investors Should Know About Agile Therapeutics Inc’s (AGRX) Financial Strength
  12. AGRX: Countdown to Dec. 26, 2017 PDUFA for Twirla®
  13. Agile Therapeutics reports 3Q loss
  14. Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017
  15. 3 Biotech Stocks to Consider Ahead of FDA Decisions
  16. Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017
  17. AGRX: Puts Forth Strong Case for Twirla® Ahead of PDUFA on Dec. 26, 2017